5 results
Primary objective: To demonstrate a clinically significant improvement in morning FEV1 in moderate to severe allergic asthmatics inadequately controlled by ICS therapy treated with QAW039 for 12 weeks compared to placebo.Secondary objectives:…
- to assess the effects of intranasal administration of oxytocin in comparison to placebo on trust, as measured by the behavioural response to the Trust game- to assess the effects of intranasal administration of oxytocin in comparison to placebo on…
Primary objective: To evaluate the efficacy of once daily doses of QAW039, as measured by EASI after 12 weeks of treatment, relative to placebo, in adult patients with moderate to severe AD. To evaluate safety and tolerability.Secondary objectives:…
In this study, the aim is to perform a home based evaluation of the SENS-UTM Bladder Sensor during the night to examine the usability of the SENS-UTM for ambulatory care in children with nocturnal enuresis.
The overall purpose of this study is to provide long-term safety data for fevipiprant (QAW039) (150 mg once daily and 450 mg once daily),compared with placebo, when added to the Global Initiative for Asthma (GINA) steps 3, 4, and 5 standard-of-care…